Drug Trial Radar · NCT04411472
(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
676
Actual
Start
Nov 2, 2020
Primary completion
Aug 18, 2022
Study completion Aug 18, 2022
Sponsor
- Lead sponsor
- AM-PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis. The study has three distinct SA-AKI trial populations: 1. The main trial population: Patients with a pre-AKI reference eGFR ≥45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization. 2. A 'moderate' CKD population: Patients with a pre-AKI reference eGFR ≥25 and \<45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization. 3. A Corona Virus Disease 2019 (COVID-19) population: Patients with proven or suspected SARS-CoV-2 at time of randomization with or without 'moderate' CKD. For patients in this population, COVID-19 should be the main cause of SA-AKI. In the main study population approximately 1400 patients will be enrolled and in the two cohorts with moderate CKD and COVID-19 each up to 100 patients. There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.
Conditions
- Acute Kidney Injury Due to Sepsis
Interventions
Recombinant human alkaline phosphataseBiological
patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- 28-day All-cause Mortality: Main Trial PopulationTime frame: 28 days
- 28-day All-cause Mortality: Moderate Chronic Kidney Disease PopulationTime frame: 28 days
- 28-day All-cause Mortality: COVID-19 PopulationTime frame: 28 days
Locations
122 sites in 15 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona
Ronald Reagan UCLA Medical Center
Los Angeles, California
The George Washington University Medical Faculty Associates - Anesthesiology
Washington D.C., District of Columbia
Emory Clinical Cardiovascular Research Institute
Atlanta, Georgia
Glenbrook Hospital
Glenview, Illinois
NorthShore Medical Group - Bannockburn
Highland Park, Illinois
University of Kentucky College of Medicine (UKCM)
Lexington, Kentucky
Regions Hospital
Saint Paul, Minnesota
University of New Mexico School of Medicine
Albuquerque, New Mexico
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
University of Cincinnati Cancer Institute
Cincinnati, Ohio
The Ohio State University - Dorothy M. Davis Heart and Lung Research Institute
Columbus, Ohio
UPMC CancerCenter at Magee - Womens Hospital
Pittsburgh, Pennsylvania
UPMC Presbyterian
Pittsburgh, Pennsylvania
University of Virginia Health System
Charlottesville, Virginia
Froedtert & the Medical College of Wisconsin Froedtert Hospital
Milwaukee, Wisconsin
Flinders Medical Centre
Bedford Park, Australia
Bendigo Hospital
Bendigo, Australia
Footscray Hospital
Footscray, Australia
Austin Hospital
Melbourne, Australia
John Hunter Hospital
New Lambton Heights, Australia
Sunshine Hospital ICU - Western Hospital
Saint Albans, Australia
Gold Coast University Hospital (GCUH)
Southport, Australia
Medizinische Universitaet Graz - Klinik fuer Innere Medizin
Graz, Austria
Medizinische Universitaet Innsbruck - Universitaetsklinik fuer Innere Medizin I
Innsbruck, Austria
Medizinische Universität Innsbruck
Innsbruck, Austria
Centre Hospitalier Universitaire Brugmann
Brussels, Belgium
Centre Hospitalier Universitaire (CHU) de Charleroi - Hopital Civil Marie Curie
Charleroi, Belgium
Ziekenhuis Oost-Limburg
Genk, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitair Ziekenhuis Brussel
Jette, Belgium
Hôpital de JOLIMONT
La Louvière, Belgium
Clinique Saint-Pierre- Ottignies
Ottignies, Belgium
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Belgium
CHU UCL Namur - Mont-Godinne
Yvoir, Belgium
Peter Lougheed Centre
Calgary, Canada
Foothills Medical Centre
Calgary, Canada
Rockyview General Hospital
Calgary, Canada
Alberta Health Services - South Health Campus Hospital
Calgary, Canada
The Ottawa Hospital - General Campus
Ottawa, Canada
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.